Workflow
Orders
icon
Search documents
X @The Economist
The Economist· 2025-07-11 09:00
Evidence suggests that hormone-replacement therapy may ease symptoms of mental disorders. Yet many patients—and even some doctors—remain wary of these treatments because because of their bad name among the public https://t.co/cuPAbI49xh ...
The Beat With Ari Melber - July 10 | Audio Only
MSNBC· 2025-07-11 00:26
Welcome to the beat. We're tracking this breaking news. President Trump losing on immigration again today. This is even after the Supreme Court recently intervened, trying to help him fend off lower courts that pause his orders when they are deemed through the process likely illegal. But that's back where the administration finds itself again tonight because the news is a rebuke from a federal judge hammering Trump with another national block of what has been this flailing effort to try to rewrite citizensh ...
Autocrat alert: Ari reports Trump has worst record for power grab orders of ANY POTUS
MSNBC· 2025-07-10 23:55
And the rule of law itself is now, according to many experts, quite clearly under siege. We're at an early point in the term. People have noticed. People are fighting back. The president of the United States is not king. What we're seeing is this administration continue to run a foul of the law. This is against the Constitution. A king unbound by laws, who rules by decree. It's going against our rights as people and especially as American citizens. What's it going to take for us to wake up? The American peo ...
CervoMed Announces Late-Breaking Presentations at Alzheimer’s Association® International Congress 2025
GlobeNewswire· 2025-07-08 11:00
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person poster presentations at Alzheimer’s Association® International Congress (AAIC) 2025, being held on July 27 – 31, 2025 in Toronto, Canada. The Company will be presenting the results, including new results, from the RewinD-LB Phase 2b study of neflamapimod i ...
Trade deals ahead of holiday orders creates certainty for retailers, says BofA's Hutchinson
CNBC Television· 2025-07-07 21:56
Um, speaking of sector impacts, BFA out with a note today looking at the impact of retailers of tariffs on Vietnam. While the levies announced last week put pressure on profits, analysts say the announcement provides some certainty ahead of the holiday order season. Joining us all here on set is the analyst behind the note, Lorine Hutchinson.Lorine, great to have you with us. Hi, thanks for having me. Thanks for coming down the block.Welcome you. It's humid outside, so it's it's a trek. Um, in terms of, you ...
How Domestic and World Orders Change
Over the last few years, three big things that hadn't happened in my lifetime prompted me to do this study. First, countries didn't have enough money to pay their debts, even after lowering interest rates to zero. So, their central banks began printing lots of money to do so.Second, big internal conflicts emerged due to growing gaps in wealth and values. This showed up in political populism and polarization between the left who want to redistribute wealth and the right who want to defend those holding the w ...
X @The Economist
The Economist· 2025-07-05 23:00
He says that thimerosal is a neurotoxin that causes neurodevelopmental disorders, notably autism, in children. An American ban on it now seems imminent. The evidence, however, strongly suggests this is a mistake https://t.co/2qQlqCU4a9 ...
Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa’s Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist
Globenewswire· 2025-07-04 07:00
Core Insights - Nxera Pharma will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals due to the initiation of clinical development of ORX142, a novel orexin receptor 2 (OX2R) agonist [1][2] - The milestone payments include US$1.8 million recognized as revenue in Q2 2025 and US$3.0 million in Q3 2025 [2] Company Overview - Nxera Pharma is a technology-driven biopharma company focused on developing specialty medicines for unmet medical needs in Japan and globally [3] - The company has established a commercial business in Japan to develop and market innovative medicines, addressing a growing market in the APAC region [3] Pipeline and Development - Nxera Pharma has an extensive pipeline of over 30 active programs, utilizing its NxWave™ discovery platform, targeting major unmet needs in neurology, metabolic diseases, and immunology [4] - The pipeline includes potentially first- and best-in-class candidates, advancing from discovery to late clinical stages in collaboration with leading pharmaceutical and biotech companies [4] Workforce and Locations - Nxera employs approximately 400 people across key locations including Tokyo, Osaka, London, Cambridge, Basel, and Seoul [5]
ISM non-manufacturing PMI 50.8 vs. 50.5 estimated
CNBC Television· 2025-07-03 14:25
First, let's get some breaking uh economic data just crossed. Rick Santelli has that for us. Rick.Yes. And there's a lot of it. If we look at the factory orders, durable goods, let's start there.Factory orders for May up 8.2%. Up 8.2%. I have five years here. I don't have a higher number. That is a huge number.And that follows a slightly revised minus 3.7% that moves to minus 3.9%. We started out the year in single digits. It certainly seems though this is telling us that all the trade pulled forward may in ...
X @Bloomberg
Bloomberg· 2025-06-30 16:00
Regulatory Landscape - Colorado is formally reviewing ibogaine for potential legal availability as a treatment for substance use disorders and mental health conditions [1] - This review could position Colorado as the first to legalize the hallucinogen for treatment purposes [1]